E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.

What Was Tested

The paper reports a study of Human Growth Hormone, published as a randomized controlled trial.

To this end, the researchers appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs.

Poststimulus GH release was quantitated by multiparameter deconvolution analysis using published biexponential kinetics and by the incremental peak serum GH concentration response (maximal poststimulus value minus prepeak nadir).

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, women only.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Human Growth Hormone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Human Growth Hormone, giving a reference point.

Blood was sampled every 10 min and serum GH concentrations were measured by chemiluminescence.

What Was Measured

Outcomes were analyzed on the logarithmic scale by mixed-effects ANOVA at a multiple-comparison type I error rate of 0.05.

Topics PubMed links to this paper include Estradiol, Feedback, Growth Hormone-Releasing Hormone, Human Growth Hormone, Oligopeptides, Postmenopause and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Human Growth Hormone.

The publication is from 2001 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.